RE:Undervalued stockYeah. That timeline was set by Shawn. The most conservative agent/mole player around but not around theralase anymore.
Toronto, Ontario – November 15, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
__________________________________________________________
November 29, 2021
The data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC, seems very encouraging, and Theralase may as well be heading towards fulfilling the necessary outcome requirements to apply for a “BTD from the FDA very soon.
Dr. Vera Madzarevic Director Clinical Development & Quality Assurance, Theralase®
__________________________________________________________
Effective October 25, 2021, Vera Madzarevic, Ph.D. assumed the role of Director of Clinical Development and Quality Assurance. Dr. Madzarevic holds a Ph.D. in both clinical pharmacology and biochemistry and brings over 25 years of global experience in clinical research and quality assurance in the biopharmaceutical and medical device industry to Theralase®.